March 11, 2010 (FinancialWire) — Vermillion, Inc. (OTC: VRML) said it has appointed a Scientific advisory board to assist in directing the company’s product development strategies.

Members of the scientific advisory board include:  

Robert C. Bast, Jr., who is vice president for Translational Research and the Harry Carothers Wiess Distinguished University Professor for Cancer Research at the University of Texas M.D. Anderson Cancer Center. Bast is best known for developing the Ovarian Cancer 125 monoclonal antibody that led to the production of the CA125 radioimmunoassay.

Walter Carney, whose Head of the Oncogene Science organization, which functions as a center of Oncology Excellence for Siemens Dx. Previously, Carney was president of Oncogene Science and Corporate officer for OSI Pharmaceuticals and also held the position of vice president of Proprietary Drug Development.

Daniel W. Chan, a Professor of Pathology, Oncology, Urology and Radiology, director of Clinical Chemistry Division, Department of Pathology, and the director, Center for Biomarker Discovery at the Johns Hopkins University School of Medicine. Chan is an authority in clinical chemistry, proteomics, immunoassay, and biochemical tumor markers.

John P. Cooke, a Professor and Associate director of the Stanford Cardiovascular Institute at Stanford University School of Medicine. He directs a translational program in vascular regeneration.

Gordon Whiteley, the director of the Antibody Characterization Lab for SAIC-Frederick, which is part of the Clinical Proteomics Technologies for Cancer Initiative of the National Cancer Institute director. Prior to coming to SAIC, he was vice president of Research and Development at PB Diagnostics / Dade-Behring where he was part of the original development team responsible for the development and commercialization of tests for a range of analytes.

California-based Vermillion is focused on the discovery, development and commercialization of novel tests used by physicians diagnose, treat and improve outcomes for patients.

Vermillion, along with its scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women’s health.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.